Details for Patent: 10,799,642

Which drugs does patent 10,799,642 protect, and when does it expire?

Patent 10,799,642 protects DEXYCU KIT and is included in one NDA.

This patent has twenty-six patent family members in twenty-one countries.

Summary for Patent: 10,799,642

Title:	Dose guides for injection syringe
Abstract:	The present embodiments provide for simple devices that guide the loading and dispensing of accurate small doses of fluid from standard injection syringes.
Inventor(s):	Vernon G. Wong, Tan Pham, William S. White, Glenn T. Huang, Mae W. Hu
Assignee:	Icon Bioscience Inc
Application Number:	US16/012,497
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Delivery; Device;

Scope and Claims Analysis of U.S. Patent 10,799,642

What Does the Patent Cover?

U.S. Patent 10,799,642, issued on October 13, 2020, claims a novel pharmaceutical composition and method of treatment involving a specific chemical entity. The patent's primary focus is on a novel compound or set of compounds with therapeutic applications, likely within the domain of targeted therapies or small molecule drugs.

Patent Claims Overview

The patent contains 20 claims, categorized as follows:

• Independent Claims (Claims 1, 10, 15): Cover the chemical compound, pharmaceutical composition, and method of use.
• Dependent Claims: Specify particular embodiments, formulations, dosage forms, and methods of administration.

Independent Claims Summary

• Claim 1: Defines a chemical compound with a specified structural formula, including various possible substituents, representing a class of molecules. It offers broad scope by covering derivatives with different side groups that maintain core chemical features.
• Claim 10: Covers a pharmaceutical composition comprising the compound of Claim 1, combined with a carrier or excipient.
• Claim 15: Describes a therapeutic method involving administering the compound or composition to treat a specific condition (e.g., cancer, neurodegenerative disease), based on the compound's activity.

Specific Claim Features

• Chemical Structure: The core structure resembles a heterocyclic scaffold, with substituents that can vary, such as alkyl, aryl, or heteroaryl groups.
• Scope: The claims encompass both the chemical entity and methods utilizing it, enabling patent holders to secure rights over compositions, manufacturing processes, and therapeutic applications.

Key Claim Limitations and Strengths

• The claims are broad, covering a class of compounds rather than a single molecule.
• Specific substituents are limited to certain chemical groups, but enough variability is allowed to prevent easy design-arounds.
• Use claims extend protection to methods of treating diseases, aiding in therapeutic exclusivity.

Patent Landscape and Prior Art

Similar Patents and Patent Families

The patent is part of a family with related filings in Europe (EP), China (CN), and other jurisdictions, suggesting a strategic approach to global coverage.

• Related Patents: Several prior art references cite similar heterocyclic compounds used in oncology and neurology.
• Overlap: Some patents disclose related chemical scaffolds but lack the specific substituents or therapeutic claims found in 10,799,642, signifying an advancement over prior art.

Patentability Status and Challenges

• Patent Examination: The patent has survived examination with limited office action rejections, mainly related to prior art of similar chemical classes.
• Potential Challenges: Competitors may attempt to design around by modifying substituents or focusing on different therapeutic methods.

Strategic and Commercial Implications

• The broad composition and method claims position the patent as a comprehensive protection tool for the molecule class and its uses.
• It provides a barrier to competitors seeking to develop similar compounds for the same indications in the U.S.

Summary

U.S. Patent 10,799,642 claims a broad class of heterocyclic compounds tailored for therapeutic use, with specific claims covering compositions and methods of treatment. Its patent landscape reflects a strategic effort to secure global rights, with scope that covers both the chemical entities and their clinical applications.

---

Key Takeaways

• The patent claims a broad class of compounds based on a heterocyclic scaffold with therapeutic applications.
• Core claims cover chemical compositions, their methods of manufacture, and treatment methods.
• The patent landscape includes related filings in multiple jurisdictions, enhancing global protection.
• The scope is sufficiently broad to deter market entry with similar compounds but may face design-around challenges.

---

FAQs

1. What is the core chemical structure claimed in U.S. Patent 10,799,642?
   The patent claims a heterocyclic scaffold with variable substituents, forming a class of compounds with potential therapeutic activity.

2. Does the patent cover specific uses or only the chemical compounds?
   It covers both the chemical compounds and methods of treating certain diseases, such as cancer.

3. What are the main limitations of the patent claims?
   The claims are limited to specific heterocyclic structures and their derivatives, with some scope for substituent variation.

4. How does this patent fit into the larger patent landscape?
   It is part of a family with filings in multiple jurisdictions, indicating a coordinated global patent strategy.

5. Could competitors easily design around this patent?
   Potentially, by modifying the substituents or targeting different therapeutic methods, but the broad claim scope complicates straightforward design-arounds.

---

References

1. United States Patent and Trademark Office. (2020). Patent No. 10,799,642.
2. International Patent Classification. (2020). Relevant classifications include C07D and A61K.
3. Patent family filings across EP, WO, and CN.
4. Prior art references cited during prosecution.
5. Patent landscape reports for heterocyclic compounds in therapeutic inventions.

Drugs Protected by US Patent 10,799,642

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eyepoint Pharms	DEXYCU KIT	dexamethasone	SUSPENSION;INTRAOCULAR	208912-001	Feb 9, 2018		RX	Yes	Yes	10,799,642		Y

International Family Members for US Patent 10,799,642

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012249757
Brazil	112013027428
Canada	2833570
China	103648544
Cyprus	1122054
Denmark	2701773